BIOTRONIK Achieves First Human Implantations of LivIQ Leadless Pacemaker
- Extending BIOTRONIK’s DX Technology to leadless pacing
- World’s first leadless pacemaker to deliver AV synchronous pacing using atrial electrical far-field signals
BIOTRONIK, a global leader in cardiovascular medical technology, today announced the successful first-in-human implantations of its LivIQ leadless pacemaker system. This was part of the BIO|CONCEPT.LivIQ study, a pre‑market clinical investigation designed to evaluate the system’s preliminary safety and performance.
The initial procedures were performed in Australia by Dr. Paul Gould at Princess Alexandra Hospital in Brisbane as well as Dr. Stewart Healy and Dr. Emily Kotschet at Victorian Heart Hospital in Melbourne. The physicians highlighted the system’s superior handling during implantation.
“I was extremely impressed with how easy the delivery system was to use,” Dr. Gould summarized his excellent initial experience. “It enables accurate and stable positioning with an added ability to simply reposition if required.” Dr. Healy and Dr. Kotschet emphasized the periprocedural visibility of both the device and delivery system, adding that “BIOTRONIK put a lot of thought into this. The visibility of the tines and the tether are excellent. The delivery system is intuitive, and easy to use.”
The BIOTRONIK LivIQ leadless pacing system is the world’s first intracardiac pacemaker to use atrial electrical far-field sensing. It enables atrioventricular (AV)-synchronous pacing at rest and during exercise with a single cardiovascular implantable electronic device (CIED). Its design simplifies implantation through intuitive handling and improved procedural visibility. The system is designed to provide reliable rate adaptation—without compromising device longevity.
“We plan to move into the global pivotal study in the coming months,” said Andreas Hecker, Chief Technology Officer at BIOTRONIK. “Introducing DX technology to leadless pacing represents a major step forward in bradycardia therapy, and we are excited to bring it to patients worldwide soon.”
Leadless pacing is increasingly adopted to reduce complications associated with traditional transvenous systems, such as lead-related issues and infection risks. BIOTRONIK’s LivIQ system aims to combine these benefits with advanced functionality, setting a new benchmark for leadless pacing technology.
- END -
CAUTION - Investigational device. Limited to federal (United States) law to investigational use.
About BIOTRONIK
For over 60 years, BIOTRONIK has stood at the forefront of medical technology, pioneering breakthrough innovations that are transforming the lives of millions affected by heart disease and chronic pain. Rooted in a deep purpose to seamlessly harmonize technology with the human body, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology. From creating Germany’s first pacemaker in 1963 to breaking new ground in digital technologies and Conduction System Pacing today, BIOTRONIK is continuously raising the bar for quality, performance, and innovation. Headquartered in Berlin, our global reach spans over 100 countries across the Americas, EMEA, and Asia—bringing bold, future-ready solutions that are shaping the next generation of medical technology.
Media Contact
BIOTRONIK Press Office: press@biotronik.com
